Seattle Genetics Reports Data from Phase I Trial of ADCETRIS® (Brentuximab ... DailyFinance ADCETRIS was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in August 2011 for two indications: (1) the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of ... |
